Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 8 October 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The forecast reflected the voluntary recall and shipment suspension of certain products in the Aortic business and temporary supply constraints in the Neuro business. Operating profit incorporates an approximately ¥3 billion impact of these factors on adjusted operating profit, as well as approximately ¥38 billion in risks related to asset values in the Aortic business and other factors.
| Item | Details |
|---|---|
| Net Sales | ¥1,229,500 million → ¥1,219,500 million（-0.8%） |
| Operating profit | ¥160,000 million → ¥119,000 million（-25.6%） |
| Profit attributable to owners of the parent | ¥120,000 million → ¥87,500 million（-27.1%） |
| Net income per share | 81.35 Yen → 59.31 Yen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 8 October 2026 |
| Previous-period results | Revenue: ¥1,131,877 million; adjusted operating profit: ¥219,369 million; operating profit: ¥176,320 million; profit attributable to owners of the parent: ¥135,914 million; basic earnings per share: ¥92.14 |
| Reason for the revision | The forecast reflected the voluntary recall and shipment suspension of certain products in the Aortic business and temporary supply constraints in the Neuro business. Operating profit incorporates an approximately ¥3 billion impact of these factors on adjusted operating profit, as well as approximately ¥38 billion in risks related to asset values in the Aortic business and other factors. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The forecast reflected the impact of the voluntary recall and shipment suspension of certain products in the Aortic business and temporary supply constraints in the Neuro business. In addition, approximately ¥38 billion in risks related to asset values, based on the Aortic business's future profitability, was incorporated.